For example, binimetinib, the most recent approved MEK1/2 inhibitor for melanoma treatment for combination therapy with a BRAF inhibitor, was able to induce at least a partial response in 20% of melanoma patients with NRAS mutations [29]. Here, MAP2K1 is linked to melanoma.